Distribution · GCC · Announced 11 Mar 2025

EQL Pharma → Pharmalink

EQL Pharma signed an exclusive deal for UAE-based Pharmalink to distribute Mellozzan (melatonin) across the six GCC states, for a six-figure euro fee paid in four milestones.

Parties: EQL Pharma (Sweden) → Pharmalink (United Arab Emirates)

Deal type
Distribution
Value
See terms
Territory
UAE, Saudi Arabia, Kuwait, Qatar, Oman, Bahrain
Therapeutic area
CNS / Neurology
Asset
Mellozzan (melatonin)
Announced
11 Mar 2025

Our analysis

Why this matters

EQL Pharma announced on 11 March 2025 an exclusive distribution agreement with Pharmalink for Mellozzan (melatonin) tablets and oral solution in the UAE, Saudi Arabia, Kuwait, Qatar, Oman and Bahrain. Mellozzan is indicated for sleep difficulties in children with ADHD and for short-term jet lag in adults. EQL receives a six-figure euro fee in four milestone payments and will hold the marketing authorisations in the region.

For BD directors at European niche-generics companies, the structure — keeping the marketing authorisation while a large regional distributor sells — preserves control of the asset in the GCC.

The full analysis is free to read with a work email on this page.

Source: EQL Pharma press release (Cision)

Latest deals

All GCC deals → · All distribution deals → · Browse all emerging-market pharma deals →